Compare HIMX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | ANIP |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2006 | 1999 |
| Metric | HIMX | ANIP |
|---|---|---|
| Price | $12.10 | $77.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 2.5M | 293.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $14.94 | $21.01 |
| Revenue Next Year | $7.79 | $17.59 |
| P/E Ratio | ★ $14.99 | $23.52 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $6.76 | $56.71 |
| 52 Week High | $12.16 | $99.50 |
| Indicator | HIMX | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 70.73 | 51.11 |
| Support Level | $8.19 | $77.19 |
| Resistance Level | N/A | $83.87 |
| Average True Range (ATR) | 0.66 | 2.70 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 96.36 | 33.92 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.